Previous Article | Next Article 
Journal of Virology, August 2000, p. 7496-7507, Vol. 74, No. 16
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Murine Model of Interstitial Cytomegalovirus
Pneumonia in Syngeneic Bone Marrow Transplantation: Persistence of
Protective Pulmonary CD8-T-Cell Infiltrates after Clearance of
Acute Infection
Jürgen
Podlech,
Rafaela
Holtappels,
Marcus-Folker
Pahl-Seibert,
Hans-Peter
Steffens,
and
Matthias J.
Reddehase*
Institute for Virology, Johannes Gutenberg
University, Hochhaus am Augustusplatz, 55101 Mainz, Germany
Received 21 March 2000/Accepted 22 May 2000
 |
ABSTRACT |
Interstitial pneumonia (IP) is a severe organ manifestation of
cytomegalovirus (CMV) disease in the immunocompromised host, in
particular in recipients of bone marrow transplantation (BMT). Diagnostic criteria for the definition of CMV-IP include clinical evidence of pneumonia together with CMV detected in bronchoalveolar lavage or lung biopsy. We have used the model of syngeneic BMT and
simultaneous infection of BALB/c mice with murine CMV for studying the
pathogenesis of CMV-IP by controlled longitudinal analysis. A
disseminated cytopathic infection of the lungs with fatal outcome was
observed only when reconstituting CD8 T cells were depleted. Neither
CD8 nor CD4 T cells mediated an immunopathogenesis of acute CMV-IP. By
contrast, after efficient hematolymphopoietic reconstitution, viral
replication in the lungs was moderate and focal. The histopathological
picture was dominated by preferential infiltration of CD8 T cells
confining viral replication to inflammatory foci. Notably, after
clearance of acute infection, CD62Llo and
CD62Lhi subsets of CD44+ memory CD8 T cells
were found to persist in lung tissue. One can thus operationally
distinguish an early CMV-positive IP (phase 1) and a late CMV-negative
IP (phase 2). According to the definition, phase 2 histopathology would
not be diagnosed as a CMV-IP and could instead be misinterpreted as a
CMV-induced immunopathology. We document here that phase 1 as well as
phase 2 pulmonary CD8 T cells are capable of exerting effector
functions and are effectual in protecting against productive infection.
We propose that antiviral "stand-by" memory-effector T cells
persist in the lungs to prevent virus recurrence from latency.
 |
INTRODUCTION |
Even though cytomegaloviruses (CMV)
typically cause disease with multiple organ involvement, the lungs are
a particularly conspicuous organ site of CMV pathogenesis, latency, and
reactivation. Specifically, CMV-associated interstitial
pneumonia/pneumonitis (CMV-IP) is the most fatal among the clinical
manifestations of human CMV (hCMV) disease in the immunocompromised
host, such as recipients of bone marrow transplantation (BMT) and solid
organ transplants, and recipients of heart-lung transplants in
particular (for reviews, see references 10, 17, 18, 43,
45, and 56). While the incidence of hCMV
infection is similar after autologous and allogeneic BMT, CMV-IP is
more common after allogeneic BMT, specifically in association with
graft-versus-host (GvH) disease (26, 27, 50, 55). However,
in the less frequent cases of CMV-IP observed after autologous BMT, the
disease was just as severe and the fatality rate was outstandingly high
(11, 25, 41).
Experimental CMV-IP occurring during lethal infection of immunodepleted
BALB/c mice with murine CMV (mCMV) confirmed the role of the lungs as a
prominent site of CMV pathogenesis in the immunodeficient host and
identified stromal and parenchymal lung cells, such as interstitial
fibrocytes, alveolar epithelial cells, and endothelial cells, as target
cells of productive mCMV infection in the absence of leukocytic
infiltrates (40). Selective exogenous reconstitution of the
infected recipients with presensitized antiviral T cells by means of
cell transfer demonstrated antiviral control (38, 40) and,
notably, also prevention of lung histopathology (39), mediated by CD8 T cells but not by CD4 T cells. The validity of this
mCMV model was proven by clinical application of T-cell transfer as a
specific preemptive cytoimmunotherapy of hCMV disease after BMT
(44), and an originally suspected immunopathology caused by
the transferred CD8 T cells was not observed in patients (for a review,
see reference 43). Extension of the mCMV infection model by a concurrent experimental BMT, either a syngeneic BMT (19, 32) or a BMT performed across a single major
histocompatibility complex (MHC) class I antigen difference (1,
33), documented a preferential recruitment of endogenously
reconstituted CD8 T cells into the infected lungs. Specifically, CD8 T
cells were recruited much more efficiently than CD4 T cells, and
recruitment to infected lungs by far exceeded the recruitment to
uninfected lungs (19). A curative antiviral rather than an
immunopathological function of CD8 T cells in pulmonary infiltrates was
concluded from four facts: (i) T-cell infiltration correlated with a
decline in virus replication (1, 19), (ii) depletion of CD8
T cells during reconstitution abolished the antiviral control with
fatal outcome (32), (iii) CD8 T cells isolated from
pulmonary infiltrates showed an ex vivo MHC-restricted cytolytic
activity against infected but not against uninfected target cells
(19), and (iv) adoptive transfer of pulmonary
infiltrate-derived CD8 T cells controlled virus replication in various
organs of indicator recipients, the lungs included (1).
While a correlation between reconstitution of CD8 T cells after BMT and
control of infection was also observed in patients (42), the
mCMV model has provided proof of the protective principle.
A special role of the lungs in the biology of CMV is also inferred from
studies on mCMV latency, reactivation, and recurrence. Thus, in the
quite diverse models of neonatal infection (3, 37) and
infection of BMT recipients (22-24, 49), the lungs consistently proved to be a prominent site of viral latency, as indicated by a high copy number of latent viral genomes and an associated high risk of transcriptional reactivation and recurrent infection upon secondary immunoablative treatment. By controlling virus
replication during acute infection, CD8 T cells limited the load of
latent viral genomes in the lungs and, accordingly, reduced the risk of
recurrent infection of the lungs (49).
While all this cumulative evidence argued for a protective role of the
immune response to mCMV as well as hCMV, Grundy et al. highly
influenced the field by proposing an immunopathogenesis of CMV-IP based
on their interpretation of clinical data as well as on data from
specifically designed murine models (13-15). In essence,
the authors highlighted the clinical data on the statistical association between CMV-IP and GvH disease, and this line of argument was supported by murine infection models in which a GvH reaction which
was experimentally enforced by administration of fairly high numbers of
mature allogeneic T cells caused lung pathology that was preventable by
immunosuppression. A second argument was the absence of CMV-IP in
athymic nude mice. A third argument was the usually benign course of
lung infection by hCMV during earlier stages of AIDS, which the authors
ascribed to a lack of CD4 T-cell-driven immunopathology. Finally,
Grundy et al. cited cases in which antiviral therapy had apparently
failed to resolve established pulmonary symptoms. Since then, the
literature on clinical CMV-IP has been filled with case reports that
interpret single clinical observations in favor or disfavor of
Grundy's immunopathogenesis hypothesis. Rebuttal came primarily from
clinicians who outlined in detail that the immunopathological
characteristics ascribed to mCMV pneumonia do not apply to most cases
of hCMV pneumonia (4, 29). Specifically, Morris
(29) concluded that the murine model is not valid.
However, the pathogenesis and histopathology of murine CMV-IP have so
far not been thoroughly studied by longitudinal analysis in a setting
of BMT that is more closely related to the clinical situation. Based on
the finding that hCMV can also result in severe CMV-IP after autologous
BMT (11, 25, 41), the present study is focused on syngeneic
BMT and on the role of CD8 T cells in mCMV-associated pathogenesis
during acute and latent infection of the lungs.
 |
MATERIALS AND METHODS |
BMT, infection, and in vivo T-cell subset depletion.
Animal
experiments were approved by the Ethics Commission, permission no.
177-07/931-17, according to German federal law. Donors and recipients
of a syngeneic experimental BMT were 8-week-old, female BALB/c
(haplotype H-2d) mice. For hematoablative
conditioning, recipients were total-body
irradiated with a single
dose of 6 Gy delivered by a 137Cs
-ray source. About
6 h after irradiation, reconstitution was initiated by intravenous
(i.v.) infusion of 5 × 106 tibial and femoral donor
bone marrow cells, isolated and depleted of mature CD8 T cells as
described previously (1). About 2 h after BMT,
recipients were infected subcutaneously in the left hind footpad with
105 PFU of purified, cell culture-propagated mCMV, strain
Smith ATCC VR-194/1981 (24). Under the specific conditions
chosen for BMT, a large number of recipients were expected to survive
the infection (19, 49). At days 7 and 14 during
reconstitution, regenerating CD4 and CD8 T-cell subsets were depleted
in vivo by i.v. infusion of 1 mg of monoclonal antibodies (MAb) YTS
191.1 and YTS 169.4 (6), respectively (kindly provided by
the group of S. Jonjic, University of Rijeka, Rijeka, Croatia). The
efficacy of the depletions was controlled by cytofluorometric analysis
as documented previously (32).
Quantitation of virus infection and T-cell infiltration in
tissues.
The in vivo infection was quantitated either by the yield
of infectious virus, measured as centrifugally enforced PFU contained in organ homogenates, or by the number of infected cells present in
lung tissue sections and detected either by in situ hybridization (ISH)
of viral DNA or by immunohistochemical staining (IHC) of viral protein.
T-cell infiltration was quantitated by IHC.
(i) Determination of virus titers in organs.
Infectious
virus was quantitated in organ homogenates by a plaque assay performed
on nearly confluent second-passage mouse fetal fibroblast monolayers
under conditions of centrifugal enhancement of infectivity as described
previously (19, 40). The virus titers represent the number
of infectious units per organ and are expressed as PFU* to indicate the
enhancement. It is worth noting that 1 PFU* corresponds to ca. 25 viral
genomes, whereas a noncentrifugal PFU represents ca. 500 viral genomes
(24).
(ii) ISH of viral DNA in intranuclear inclusion bodies.
Detection of viral DNA was performed as described previously
(32). In essence, in order to get an optimal sensitivity of detection, a mixture of digoxigenin (digoxigenin-11-dUTP)-tagged plasmids containing HindIII fragments A, I, and K,
altogether representing 51.2 kbp of the mCMV Smith genome, was used as
the specific probe. Labeling was performed with alkaline
phosphatase-conjugated antidigoxigenin antibody and new fuchsin as the
substrate, yielding a brilliant red. ISH detects infected cells in the
late phase of viral replication, when viral DNA accumulates for
packaging and nucleocapsid assembly in an intranuclear inclusion body.
(iii) Two-color IHC.
Infected lung cells and
lung-infiltrating T cells were simultaneously visualized in 2-µm
paraffin-embedded sections of lung tissue by two-color IHC as described
in detail previously (19). In essence, infected lung cells
were visualized by detection of intranuclear viral IE1 protein with MAb
CROMA 101 (kindly provided by S. Jonjic, University of Rijeka) using
the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method with
new fuchsin as the substrate (red staining). T cells were visualized by
staining of membrane CD3
, using the avidin-biotin-peroxidase complex
(ABC) method with diaminobenzidine tetrahydrochloride as the substrate,
followed by enhancement with nickel sulfate hexahydrate (black
staining). Viral IE1 protein is present in the nucleus of the infected
cell throughout the viral replication cycle. Therefore, IE1-specific
IHC detects more infected cells than does ISH. In our experience, the
ratio between IHC-positive and ISH-positive cells is ca. 2:1 during
florid infection of permissive tissues.
(iv) Quantitation of histological data.
To avoid artificial
compression of lung tissue, it was crucial to distend alveolar spaces
by instillation of the fixative (phosphate-buffered saline [PBS] [pH
7.4] containing 4% [vol/vol] formalin) into the trachea. The
numbers of infected tissue cells (red) and infiltrating T cells (black)
were counted for representative areas of tissue sections (in the case
of the lungs, usually 100-mm2 areas) compiled from sections
representing the organ morphology and taken in distances from each
other (>10 µm) chosen to exclude redundant counting of the same
cells. Numbers of infected tissue cells were related to the number of
lung cells counted in uninfected lung tissue after hematoxylin staining
of nuclei. It should be mentioned that infiltrating leukocytes were
found not to be infected, with the exception of a very few alveolar
macrophages. Therefore, the reported percentage of infected cells in
the lungs refers to the stromal-parenchymal compartment. An estimate of
the total number of infected cells per lung was made by relating
section volumes (2 µm by 100 mm2) to the average total
volume of a lung embedded in paraffin (0.135 cm3). The
extrapolation to the total organ volume results in an overestimation because sections may cut the same nucleus more than once depending on
the ratio between nucleus (assumed to be a sphere) diameter, D, and thickness of the tissue section, d.
Extrapolated numbers N* were corrected by using the
empirical formula N = N* × d/D. Since nuclei, in
particular those of endothelial cells, are ellipsoids rather than
spheres, and since the size and form of nuclei differ between cell
types in the lungs, the estimate should be seen as a rough
approximation to give an impression of the order of magnitude.
Isolation and immunomagnetic enrichment of pulmonary CD8 T
cells.
Mononuclear leukocytes were isolated from lung tissue as
described previously (19) by collagenase-DNase digestion of
lung parenchyma followed by Ficoll density gradient centrifugation. Analyses were performed with cells pooled from at least 10 mice per
group. It is important to emphasize that intravascular leukocytes had
been largely removed by perfusion, but the presence of intracapillary leukocytes that stick to endothelial cells can never be excluded. Cells
were either used directly for cytofluorometric analyses of the
phenotypes present in the pulmonary infiltrate population (see below)
or were subjected to positive immunomagnetic sorting (MiniMacs
separation unit; Miltenyi Biotec Systems, Bergisch-Gladbach, Germany)
for the purification of CD8 T cells (anti-CD8a MicroBeads, catalog no.
494-01; Miltenyi Biotec Systems) as described in more detail previously
(1). The purity of the population was found to be ca. 96%
as determined by cytofluorometric reanalysis with phycoerythrin
(PE)-conjugated MAb anti-CD8a (clone 53-6.7, rat immunoglobulin G2a
[IgG2a]; catalog no. 01045A; PharMingen, San Diego, Calif.).
Assay of CD3
-redirected cytolytic activity.
The CD3
assay measures the total cytolytic potential of an effector cell
population by antigen-independent polyclonal signaling via the T-cell
receptor (TCR)-CD3 complex. Target cells were 51Cr-labeled
Fc receptor-expressing P815 mastocytoma cells armed with Fc
receptor-bound anti-CD3
MAb. Immunomagnetically purified pulmonary
CD8 T cells were tested as effector cells. A standard 4-h
51Cr release assay was performed with graded numbers of
effector cells and with 103 target cells per 0.2-ml
microwell. Data represent the mean percentage of specific lysis from
three replicate cultures. It should be recalled from previous work that
P815 cells are not lysed by mCMV-activated pulmonary infiltrate T cells
in the absence of anti-CD3
MAb and that no cytolytic activity was
triggered by anti-CD3
MAb in unprimed T cells isolated from the
lungs after BMT with no infection (19).
Three-color cytofluorometric analyses.
Cytofluorometric
analyses were performed with a FACSort (Becton Dickinson, San Jose,
Calif.) by using CellQuest software (Becton Dickinson) for data
processing. Overlaps in the emission spectra of fluorescent dyes were
compensated for throughout, and thresholds were set in the
forward-versus-side scatter (FSC-vs-SSC) plot to exclude particles the
size of erythrocytes or smaller and to exclude dead cells during data
acquisition. For calculations, a "lymphocyte gate" was set in the
FSC-vs-SSC plot so as to largely exclude macrophages and residual
granulocytes from the analysis but include all living T cells. Staining
for the expression of TCR
/
(see below) was used to define the
lymphocyte gate. This is of particular importance, since the scatter
characteristics of activated pulmonary infiltrate T cells differ
somewhat from those of resting T cells in lymphoid organs. Basic
technical aspects, such as the preparation of cells for
cytofluorometric analysis, the composition of buffers, and the blocking
of nonspecific binding sites, have been described previously
(1). Throughout, fluorescence channel 1 (FL-1) represents
the fluorochrome fluorescein (fluorescein isothiocyanate; FITC), FL-2
represents the fluorochrome R-PE, and FL-3 represents either the tandem
fluorochrome PE-Cy5, also known as Cy-Chrome, or the tandem
fluorochrome PE-Texas Red, also known as RED613 or duochrome.
(i) Determination of CD8/CD4 subset ratios among
/
T
cells.
Pulmonary infiltrate cells retrieved from the Ficoll
interphase were labeled with FITC-conjugated MAb anti-CD8 (clone
53-6.7, rat IgG2a; catalog no. 01044A; Becton Dickinson), PE-conjugated MAb anti-TCR
/
(clone H57-597, hamster IgG; catalog no. 01305A; PharMingen), and PE-Cy5-conjugated MAb anti-CD4 (clone H129.19, rat
IgG2a; catalog no. 09008A; PharMingen). The analysis was restricted to
/
T cells by setting an electronic gate on signals with positive FL-2.
(ii) CD44 and CD62L activation phenotyping of CD8 T cells.
Pulmonary infiltrate cells retrieved from the Ficoll interphase were
labeled with FITC-conjugated MAb anti-CD44 (clone IM7, rat IgG2b;
catalog no. 01224D; PharMingen) and PE-conjugated MAb anti-CD8a (see
above). CD62L was labeled indirectly with biotinylated MAb anti-CD62L
(clone MEL-14, rat IgG2a; catalog no. 01262D; PharMingen) and
streptavidin-RED613 (catalog no. 19541-010; Life Technologies). The
analysis was restricted to CD8 T cells by setting an electronic gate on
signals with positive FL-2.
(iii) Detection of intracellular IFN-
.
The functional
capacity of pulmonary CD8 T cells to produce gamma interferon (IFN-
)
(35) was tested by antigen-independent polyclonal signaling
via the TCR-CD3 complex. Pulmonary infiltrate cells retrieved from the
Ficoll interphase were seeded in replicate 0.2-ml cultures in 96-well
round-bottomed microwell plates at a concentration of 106
cells per culture. The composition of the culture medium, which included 10 µg of brefeldin A per ml, was described previously (20). For polyclonal signaling, cells were stimulated with
0.4 µg (per culture, i.e., per 106 cells) of MAb
anti-CD3
(clone 145-2C11, hamster IgG; Dianova catalog no. 1530-14;
Southern Biotechnology Associates Inc., Birmingham, Ala.). It should be
noted that a log2 titration of anti-CD3
from 0.2 to 1.6 µg gave
identical results (data not shown). The cells were harvested after
5 h of incubation and processed for cytofluorometric analysis as
described previously (20). Surface staining was performed
with FITC-conjugated anti-CD62L (clone MEL-14, rat IgG2a; catalog no.
01264D; PharMingen) and PE-Cy5-conjugated MAb anti-CD8a (clone 53-6.7, rat IgG2a; catalog no. 01048A; PharMingen). After washing, cell
fixation was performed for 20 min at ca. 20°C by addition of 100 µl
of PBS containing 2% (vol/vol) paraformaldehyde. Cells were washed to
remove the fixative and permeabilized as described (20). For
intracellular IFN-
staining, an aliquot of 2 × 106
cells was labeled with 0.05 µg of PE-conjugated MAb anti mouse IFN-
(clone XMG1.2, rat IgG1; catalog no. 18115A; PharMingen). For
isotype control, another aliquot was incubated with 0.05 µg of
PE-conjugated rat IgG1 (clone R3-34, isotype control rat IgG1; catalog
no. 20615A; PharMingen).
Analysis of in vivo antiviral activity of pulmonary CD8 T cells
by adoptive transfer.
Recipients of adoptive cell transfer were
8-week-old, female BALB/c mice that were immunosuppressed by
irradiation with a dose of 6.5 Gy and infected in the left hind footpad
with 105 PFU of purified mCMV. Under these conditions, all
mice die of multiple-organ CMV disease (40) between days 10 and 18 after infection unless they receive protective T cells
(39). Graded numbers of immunomagnetically purified
pulmonary CD8 T cells (see above) were transferred i.v. 6 h after
irradiation and 2 h before infection, and antiviral function
was assessed for lungs and spleen of the recipients on day 12 after
infection by virus plaque assay.
 |
RESULTS |
Control of pulmonary mCMV infection after BMT depends on CD8 T-cell
reconstitution.
Syngeneic BMT was performed with concomitant
experimental mCMV infection. Based on previous work in this model
(19, 32, 49), conditions of BMT and infection were chosen to
permit a high survival rate of the recipients due to successful and
timely hematopoietic reconstitution. In the particular experiment shown in Fig. 1, all recipients survived long
term (Fig. 1A, solid squares). The protective principle within the
reconstituting myeloid and lymphoid cell lineages was revealed by
specific in vivo depletion of T-cell subsets during the process of
reconstitution after BMT. The efficacy of the depletions was controlled
by cytofluorometric analysis of pulmonary infiltrate cells. In
accordance with a previous report (32), depletion reduced
the respective T-cell subsets to
0.5% of the T cells (not shown
here). Selective depletion of CD4-positive cells, which includes CD4 T
cells and subsets of bone marrow myeloid cells, had no significant
effect on the survival rate (Fig. 1A, solid circles). By contrast,
selective depletion of CD8 T cells inevitably resulted in death from
the disease within 3 weeks (Fig. 1A, open circles). Simultaneous
depletion of both T-cell subsets did not accelerate the lethal course
(Fig. 1A, open squares). It must be emphasized that depletion of CD8 T
cells is not associated with lethal disease after BMT in the absence of
infection (not shown). In accordance with previous work
(32; for a review, see reference
21), this experiment has thus unequivocally
identified CD8 T cells as the protective principle preventing
CMV-associated mortality after BMT. CD4 T cells were not required for
protection, nor could they functionally substitute for the eliminated
CD8 T cells in this particular experimental setting. The result is also
decisive regarding the controversial hypotheses of "viral
pathogenesis" versus "immunopathogenesis" of CMV disease.
Recipients survived when CD8 T cells or both CD8 and CD4 T cells were
present, and they died when CD8 T cells or both subsets were absent.
Thus, clearly, the observed lethal outcome of mCMV infection was not
the result of an immunopathology.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Role of T-cell subsets in the control of CMV disease
during hematopoietic reconstitution. (A) Effect of selective T-cell
subset depletion on survival rate. BMT and mCMV infection were
performed on day 0, and T-cell subsets were depleted by two consecutive
(on days 7 and 14) i.v. infusions of MAbs directed against CD4 or CD8.
Shown are Kaplan-Meyer plots for 10 recipients per group. Solid and
open symbols indicate the presence and absence of CD8 T cells,
respectively. (B) Effect of selective T-cell subset depletion on mCMV
replication in the lungs. With additional recipients in each of the
four experimental groups, the number of infected lung tissue cells was
determined by quantitative viral DNA ISH on day 19, that is, at a stage
when CMV disease was prefinal in CD8-depleted recipients. Symbols
correspond to those in panel A and represent data from individual
recipients. The median value is marked by a horizontal bar. The
left-hand scale shows the absolute numbers of ISH-positive lung cells
present in representative 100-mm2 areas compiled from lung
tissue sections. The right-hand scale relates these numbers to the
number of nucleated stromal and parenchymal cells detected by
hematoxylin staining. The total number of lung cells is ca. 6 × 107.
|
|
Since CMV disease is characterized by multiple-organ involvement
(18, 32), one could argue that CD8 T cells prevent a lethal
course of disease by controlling virus replication at vital tissue
sites, including liver, adrenal glands, and the bone marrow stroma
(9, 32), but contribute to pathogenesis specifically in the
lungs. As a first approach to understanding the role of CD8 T cells in
the lungs, we quantitated the infection of lung tissue in relation to
the presence of T-cell subsets by counting the number of productively
infected lung cells. Productive infection was visualized by ISH
staining of viral DNA accumulated in intranuclear inclusion bodies
during viral DNA packaging and nucleocapsid assembly in the late phase
of the viral replication cycle. The analysis was performed at day 19 after BMT and infection, that is, at a prefinal stage of CMV disease
(Fig. 1B). The extent of infection of the lungs precisely reflected the
overall course of disease. In the two experimental groups with
reconstituting CD8 T cells (Fig. 1B, solid symbols), the proportion of
infected lung cells was between 0.01 and 0.1%, whereas in both groups
that were depleted of CD8 T cells (open symbols), between 1 and 3% of
the stromal and parenchymal lung cells, in absolute terms ca. 0.6 × 106 to 1.8 × 106 cells, were found to
be in the late phase of infection. In conclusion, reconstitution of CD8
T cells after BMT is essential to prevent massive infection of the lungs.
Viral histopathology in lungs devoid of T-cell infiltrates.
The histopathological consequences of viral replication and T-cell
control in the lungs were studied by two-color IHC, simultaneously visualizing infected cells by red staining of intranuclear viral IE1
protein and infiltrating T cells by black membrane staining of CD3
(Fig. 2).

View larger version (173K):
[in this window]
[in a new window]
|
FIG. 2.
Viral histopathology in the lungs after T-cell subset
depletion. A two-color IHC analysis of lung tissue was performed on day
19 after BMT and mCMV infection (corresponding to Fig. 1) for
recipients depleted either selectively of CD4 T cells (A1, overview;
A2, details) or depleted of both T-cell subsets (B1, overview; B2,
details). Infected cells are visualized by red staining of intranuclear
viral IE1 protein, and infiltrating T cells are visualized by black
staining of membrane CD3 . Counterstaining was performed with
hematoxylin. The arrows in panel A2 point to uninfected alveolar
macrophages recruited to the inflammatory focus. Bars, 25 µm.
|
|
In the experimental group that was selectively depleted of CD4 T cells,
infected cells were rare in the lungs and were actually not seen in
every tissue section. Notably, infiltrating blastoid CD8 T cells were
not distributed randomly in lung tissue but formed inflammatory foci
specifically at the sites at which infected lung cells were located
(Fig. 2, panel A1 for overview and A2 for details). Alveolar
macrophages were also recruited into these foci (Fig. 2A2). As a side
aspect, one should note that the alveolar macrophages shown in Fig. 2A2
did not express detectable IE1 protein. From this part of the
experiment, we draw the following conclusions: (i) extravasation and
recruitment of CD8 T cells to the site of infection do not require help
by CD4 T cells, (ii) infiltrating CD8 T cells focus their action
towards infected cells, and (iii) in reverse conclusion, CD8 T cells do
not damage uninfected parts of tissue, at least not by cell-to-cell
delivery of effector functions.
A strikingly different picture was seen when both T-cell subsets were
depleted during reconstitution (Fig. 2, panel B1 for overview and B2
for details). Numerous infected cells, distributed randomly throughout
the lung parenchyma, were now detected in every tissue section. By cell
counting in representative 100-mm2 areas of lung tissue,
the proportion of IE1-expressing cells was found to range between ca. 2 and 6%. Complete absence of CD3
staining gives visible proof of the
efficacy of T-cell depletion. Alveolar macrophages were frequent but
were not found colocalized to infected cells (Fig. 2B1). Altogether,
focal infection, as it was seen in the presence of CD8 T cells, was
here replaced by disseminated infection. A comparison of the overall
tissue architecture (Fig. 2, compare panels A and B) shows a more
pronounced widening of alveolar septa and a higher degree of alveolar
collapse in the absence of T-cell infiltrates! From this part of the
experiment, we draw the following conclusions. (i) Infection of the
lungs bursts in the absence of CD8 T cells. In the reverse conclusion, the CD8 T cells shown in Fig. 2A were antivirally active and
responsible for limiting the spread of infection in the lungs. (ii)
Histopathological characteristics of disseminated interstitial
pneumonia develop in absence of T cells, that is, neither CD8 T cells
nor CD4 T cells cause the histopathological alterations seen in the
acute phase of CMV infection.
In conclusion, the lung pathology found after BMT and acute CMV
infection is not a CMV-associated T-cell-mediated immunopathology but represents an authentic viral pneumonia.
Persistence of T-cell infiltrates after clearance of productive
infection.
Efficient reconstitution of antiviral CD8 T cells after
BMT leads to control of CMV infection and prevents a lethal course of
disease, but there might be sequelae accounting for late CMV-associated morbidity in survivors of acute CMV disease (5). We
therefore performed a longitudinal study of pulmonary infection and
T-cell infiltration by two-color IHC, correlating the number of T cells in the lungs with the number of infected cells for an observation period of 10 months after BMT and primary infection, with no
experimental depletion of T-cell subsets performed (Fig.
3). In accordance with previous data on
the yield of infectious virus (19), the number of infected
lung cells reached its peak after 3 weeks and declined sharply
thereafter. By 5 weeks, productive infection was resolved. It should be
recalled from previous work that the viral genome is not cleared from
the lungs but is maintained in a state of latency (22, 24).
Infiltration of T cells paralleled the infection during the first 3 weeks, but the infiltrates persisted long term, with only a slow and
moderate decline in cell numbers during the observation period (Fig.
3A). By extrapolation, one can predict that infiltrates persist for the
life span of the recipients. On the basis of this kinetics, we can now
operationally define two phases of CMV-associated histopathology. Phase
1 is defined by the simultaneous presence of infected lung cells and T-cell infiltrates, whereas phase 2 is defined by the presence of
T-cell infiltrates in the absence of productive infection. Histopathology representative of these two defined phases is documented in Fig. 3B for the third week (Fig. 3B1, phase 1) and for the third
month (Fig. 3B2, phase 2). Figure 3B1 shows a perivascular inflammatory
focus with colocalization of infected cells (red) and infiltrating
blastoid T cells (black). By contrast, Fig. 3B2 documents a scattered
distribution of small, apparently resting T cells (black) in lung
parenchyma in the absence of infected cells. The tissue architecture in
this late phase is not severely impaired, which is consistent with
long-term survival of the recipients and which implies that neither CD8
nor CD4 T cells cause visible tissue damage. In fact, the presence of
interstitial T cells is the only significant histopathological sign. In
summary, phase 1 histopathology can be characterized as a CMV-positive
IP with inflammatory foci, whereas phase 2 histopathology can be
characterized as a diffuse and very moderate CMV-negative IP with
marked T-cell presence in the interstitium and little involvement of
alveolar spaces. From a pathologist's point of view, and with no
further information being provided, phase 2 histopathology in
clinically asymptomatic BMT recipients would not easily be diagnosed as
being associated with CMV. Rather, the presence of T-cell infiltrates in the absence of an infectious agent may tempt one to diagnose an
"idiopathic" pneumonia or an immunopathological condition of unknown etiology. That it is in fact an "aged" CMV pneumonia is only revealed by longitudinal analysis of the events.

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 3.
Longitudinal analysis of pulmonary infection and T-cell
infiltration after BMT. Histopathology in the lungs was studied by
quantitative two-color IHC, with infected cells being visualized by red
staining of intranuclear viral IE1 protein (red dots) and infiltrating
T cells by black staining of membrane CD3 (black dots). (A) Time
course of infection and T-cell infiltration. Each symbol represents
data for individual recipients. The lines connect median values.
Negative counts are depicted only on the first occasion in the kinetics
and remained negative throughout. The left-hand scale and the
right-hand scale show the numbers of infected lung cells and of
lung-infiltrating T cells, respectively, for representative
100-mm2 areas compiled from several lung tissue sections.
In a control group receiving BMT but not infection, the tissue
architecture was not pathologically altered (19) (not
shown), and in phase 2, the average number of T cells per 100 mm2 was 880 (arrowhead), in comparison to ca. 200 in lungs
of normal mice. (B) Examples of lung histology representative of phase
1 (B1, CMV-positive IP) and of phase 2 (B2, CMV-negative IP). (B1)
Perivascular inflammatory focus seen 3 weeks after BMT and infection in
tissue that connects two neighboring vessels. T cells located within
the inflammatory focus are activated lymphoblasts, as shown by
halo-like membrane staining (see also Fig. 2A2). (B2) Random
distribution of residual interstitial T cells after clearance of
productive infection, as observed after 3 months. Note that most of the
T cells (some of which are marked by an arrow) are considerably smaller
than those in phase 1 and apparently represent resting cells.
Counterstaining was performed with hematoxylin. Bars, 25 µm.
|
|
Activation phenotypes of phase 1 and 2 pulmonary CD8 T cells.
While the preceding experiments have provided conclusive evidence for a
protective role of infiltrating CD8 T cells during phase 1, a
contribution to late histopathology still has to be considered. As a
first approach to understanding the role of CD8 T cells during phase 2, we isolated lymphocytes from phase 1 and 2 pulmonary infiltrates for a
comparative cytofluorometric analysis of their phenotypes (Fig.
4). In accordance with our previous work
(19), the T-cell population in the phase 1 infiltrates was
largely dominated by CD8 T cells. It is instructive to recall from the
previous work that the CD8/CD4 T-cell ratio in lung infiltrates is ca.
0.2 after BMT with no mCMV infection, as it is in normal lungs of
immunocompetent BALB/c mice (19), whereas this ratio was 2.3 in phase 1 infiltrates of the experiment documented in Fig. 4A. In
phase 2, the absolute number of T cells in lung tissue had declined by
a factor of ca. 10 (recall Fig. 3A). In addition, the CD8/CD4 ratio had
declined to 0.5 (Fig. 4B). Thus, the absolute number of CD8 T cells had
actually declined significantly between phase 1 and phase 2, by a
factor of ca. 20. The CD44 cell surface glycoprotein (also called Pgp-1
and Ly-24) is required for extravasation of activated T cells into an
inflammatory site (8). Accordingly, CD8 T cells isolated
from pulmonary infiltrates all expressed CD44, regardless of whether
they were isolated during phase 1 or phase 2 (Fig. 4C and D). Like
CD44, the CD62L member of the selectin family (also called
L-selectin, Ly-22, and MEL-14 antigen) contributes to the
recruitment of leukocytes into areas of inflammation by mediating their
initial tethering and rolling on endothelial surfaces. However, upon
activation of lymphocytes, CD62L is rapidly shed from the cell surface
as a result of proteolytic cleavage (12, 54; for a
review, see reference 53). Activated cells are
therefore supposed to display the phenotype CD44hi
CD62Llo, and naive T cells and quiescent memory T cells are
supposed to display the phenotypes CD44lo
CD62Lhi and CD44hi CD62Lhi,
respectively (28; for a review, see reference
2). In phase 1 pulmonary infiltrates, 90% of the
CD8 T cells showed the phenotype of activated cells (Fig. 4C). This
finding is in agreement with the antiviral effector function performed
by CD8 T cells during acute infection of the lungs. Note that the few
CD62Lhi CD8 T cells seen in phase 1 were
CD44lo. These cells likely represent naive CD8 T cells,
probably residual intracapillary leukocytes. In phase 2 pulmonary
infiltrates, the activated population was still prominent (ca. 71%),
but a significant population of CD44hi CD62Lhi
memory T cells (ca. 22%) had emerged in the infiltrates (Fig. 4D). For
completeness, it should be mentioned that a small population (ca. 7%)
of CD62Ldim CD8 T cells was present in both phases. We do
not presently know any role for these cells. In conclusion, the
cellular composition of phase 1 and phase 2 pulmonary infiltrate T-cell
populations differs in that the proportion of CD8 T cells is reduced in
phase 2 while the number of CD8 T cells with memory phenotype is
increased. However, the proportion of CD8 T cells with the activation
phenotype CD44hi CD62Llo is still quite
considerable in phase 2.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 4.
Phenotypes of phase 1 and phase 2 pulmonary infiltrate T
cells. Pulmonary infiltrate cells were isolated at 4 weeks (phase 1)
and at 10 weeks (early in phase 2) after BMT and mCMV infection. (A and
B) Three-color cytofluorometric analysis was performed for the marker
combinations FITC (FL-1)-CD8, PE (FL-2)-TCR / , and PE-Cy5
(FL-3)-CD4. A gate was set on lymphocytes, and the analysis was
restricted to ca. 20,000 / T cells by a second gate set on
positive FL-2. (C and D) Three-color cytofluorometric analysis was
performed for the marker combinations FITC (FL-1)-CD44, PE (FL-2)-CD8,
and RED613 (FL-3)-CD62L. A gate was set on lymphocytes, and the
analysis was restricted to ca. 10,000 CD8 T cells by a second gate set
on positive FL-2. FL-3 (ordinate) versus FL-1 (abscissa) log
fluorescence intensities are shown for gated cells as contour plots in
a 70% log-density mode (threshold, 2%; smoothing factor, 5).
Percentages of relevant T-cell subsets and the ratios of CD8 to CD4 T
cells (CD8/CD4) are indicated.
|
|
Functional properties of phase 1 and 2 CD8 T cells.
The
finding that a considerable number of phase 2 pulmonary infiltrate CD8
T cells still displayed the phenotype of activated T cells suggested a
functional activity. Since the proportion of CD8 T cells specific for
any single antigenic peptide of mCMV is proposed to be very low, as it
was concluded previously for the immunodominant IE1 peptide
(19), the antigen-independent method of eliciting effector
function by polyclonal signaling via the CD3-TCR complex was chosen to
measure the functional competence of whole CD8 populations.
Specifically, the cytolytic potential of immunomagnetically purified
phase 1 and 2 pulmonary infiltrate CD8 T cells was tested by
CD3
-redirected lysis. In accordance with previous work
(19), phase 1 CD8 T cells were cytolytically active (Fig.
5). Notably, even though with somewhat
lower cytolytic potential, purified phase 2 CD8 T cells were also
functional in this assay (Fig. 5). Accordingly, analysis of perforin
gene expression by reverse transcriptase-PCR revealed a similar amount
of perforin transcripts for phase 1 and 2 pulmonary infiltrate CD8 T
cells in this particular experiment (not shown). It should be
mentioned, however, that cytolytic activity during phase 2 is variable
and that detection of low activities in the infiltrates requires
enrichment for CD8 T cells. From previous work (19) it
should be recalled that cytolytic activity is undetectable throughout
the kinetics in pulmonary infiltrates after BMT performed in the
absence of infection. In conclusion, the experiment has demonstrated
that phase 2 CD8 T cells, at least some of them, possess the capacity to exert cytolytic effector function upon engaging their CD3-TCR complex. This quality is dependent upon prior sensitization during a
preceding infection of the lungs.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Cytolytic activity of pulmonary infiltrate CD8 T cells
after polyclonal CD3 signaling. Immunomagnetically purified CD8 T
cells (phase 1, 4 weeks; phase 2, 16 weeks) were tested for cytolytic
activity by the assay of CD3 -redirected lysis with
effector-to-target cell ratios (E/T) as indicated. Note that T cells
isolated from lungs after BMT with no infection did not exert
detectable cytolytic activity at an E/T ratio of 40 (data not shown
here; see reference 19).
|
|
The expression of IFN-
is another relevant effector quality of CD8 T
cells. The capacity to synthesize IFN-
upon polyclonal signaling via
the CD3-TCR complex was tested for phase 1 and 2 pulmonary infiltrate
cells by stimulation with MAb anti-CD3
(Fig. 6A). For comparison, pulmonary T cells
isolated at the same time post-BMT from the lungs of uninfected BMT
recipients were analyzed accordingly (Fig. 6B). Three-color
cytofluorometric analysis was used to combine cell phenotyping for
expression of CD8 and CD62L with measurement of accumulated
intracellular IFN-
.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 6.
Production of IFN- after polyclonal CD3 signaling.
(A) BMT and mCMV infection. (B) BMT with no infection. Pulmonary
infiltrate cells (phase 1, 4 weeks; phase 2, 16 weeks) were stimulated
for 5 h with MAb anti-CD3 in the presence of brefeldin A. Control groups were treated accordingly except for polyclonal CD3
stimulation. Three-color cytofluorometric analysis was performed for
the marker combination FITC (FL-1)-CD62L, PE (FL-2)-IFN- , and PE-Cy5
(FL-3)-CD8. A gate was set on lymphocytes, and the analysis was
restricted to ca. 25,000 CD8 T cells by a second gate set on positive
FL-3. FL-1 (ordinate) versus FL-2 (abscissa) log fluorescence
intensities are shown for gated cells as dot plots, with 10,000 dots
displayed. Percentages are indicated for CD62Lhi CD8 T
cells (upper left quadrants) and for CD62Llo CD8 T cells
with intracellular accumulation of IFN- (lower right quadrants). The
isotype controls (PE-conjugated rat IgG1) are shown for cells
stimulated with anti-CD3 .
|
|
In phase 1 after infection (Fig. 6A, left panel), ca. 36% of the gated
CD8 T cells were capable of expressing IFN-
, and these cells
displayed the CD62Llo phenotype. The few
CD62Lhi cells (ca. 20%) were mostly refractory to
stimulation by anti-CD3
. In accordance with their CD44lo
phenotype (recall Fig. 4), this finding is indicative of naive cells.
It should be noted that IFN-
expression discriminates between two
qualitatively different subsets of CD8+ CD62Llo
T cells. We concluded this from the finding that intensification of the
triggering by higher doses of MAb anti-CD3
did not increase the
number of responding cells (not shown). After BMT with no infection
(Fig. 6B, left panel), many more CD8 T cells in phase 1 (ca. 72%)
displayed the CD62Lhi phenotype of resting cells and
accordingly, most of these cells (ca. 63% of the CD8 T cells) were
also refractory to stimulation by anti-CD3
. CD8 T cells producing
IFN-
were less frequent than after infection (ca. 11% versus ca.
36%), but were also of the CD62Llo phenotype.
In phase 2 after infection (Fig. 6A, right panel), the percentage of
CD62Lhi CD8 T cells was elevated (ca. 40% versus ca. 20%
in phase 1) and the percentage of CD62Llo IFN-
producers
was still substantial, ca. 26%. Remarkably, unlike in phase 1, many of
the CD62Lhi cells were now susceptible to stimulation by
anti-CD3
, as is indicated by the shift to a CD62Llo
phenotype. This feature is consistent with the known loss of CD62L upon
activation of quiescent memory CD8 T cells to memory effector cells
(28). After BMT with no infection (Fig. 6B, right panel),
many cells among the prevalent CD62Lhi population also
showed a memory-type downregulation of CD62L in response to stimulation
with anti-CD3
, but only a few CD62Llo cells (ca. 6% of
the CD8 T cells) were able to respond with production of IFN-
.
In conclusion, infection alters the pulmonary CD8 T-cell population
quantitatively and qualitatively. It increases the absolute and
relative number of CD8 T cells that can respond to a CD3-TCR-mediated stimulus with the production of IFN-
.
Phase 1 and phase 2 pulmonary infiltrate CD8 T cells protect
against productive infection.
The finding that "stand-by"
effector cells persist in the lungs for many months after clearance of
the productive infection raised the question of their functional role,
immunopathology or antiviral surveillance. Evidence in favor of
antiviral surveillance was provided by adoptive transfer of
immunomagnetically purified phase 1 and 2 pulmonary infiltrate CD8 T
cells into immunocompromised and lethally infected indicator
recipients. Pulmonary CD8 T cells derived from both phases controlled
the acute infection in a dose-dependent manner not only at the site of
origination, namely in the lungs, but also in the spleen (Fig.
7) and in other organs of the indicator recipients (not shown). Notably, the efficacy per cell was even somewhat higher in phase 2.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 7.
Comparison of the in vivo antiviral function of phase 1 and phase 2 CD8 T cells. Graded numbers of immunomagnetically purified
pulmonary infiltrate CD8 T cells (phase 1, 4 weeks; phase 2, 12 weeks)
were transferred by i.v. infusion into immunocompromised and infected
indicator recipients. Infectious virus in lungs and spleen of the
recipients was measured on day 12 after infection and cell transfer by
a virus plaque assay. PFU*, PFU determined under conditions of
centrifugal enhancement of infectivity. Dots represent individual
transfer recipients. The median values are marked by a horizontal bar.
The dotted line indicates the detection limit (DL) of the assay. Ø,
positive control of virus replication in the absence of cell
transfer.
|
|
In conclusion, phase 2 pulmonary infiltrate CD8 T cells can exert an
antiviral effector function in vivo.
 |
DISCUSSION |
Since the time when Grundy et al. (14) postulated an
immunopathogenesis triggered by CMV infection, the pathogenesis of CMV-IP has been a matter of ongoing debate. While a number of pros and
cons have meanwhile been collected from clinical data and murine models
(for reviews, see references 4 and
29), a systematic study of lung histopathology after
CMV infection in the specific context of BMT was clearly missing.
Murine models of GvH disease and mCMV infection have been used to
advocate the immunopathogenesis hypothesis (14, 15, 46),
although these models were by design unrelated to the particular
conditions imposed by the kinetics of hematopoietic and lymphopoietic
reconstitution after BMT. A model of allogeneic BMT in the rat
confirmed the postulated correlation between GvH immunogenetics of the
transplantation and CMV-IP but did not confirm immunological symptoms
of a GvH disease (48) as it was proposed by the
immunopathogenesis hypothesis. Likewise, we have evidence for murine
CMV-IP caused in the absence of GvH disease by extensive virus
replication resulting from a failure in antiviral CD8 T-cell control
after BMT performed across an MHC class I difference (31,
33). In the present report, a murine model of syngeneic BMT was
used to study the time course of CMV-associated histopathology of the
lungs under conditions of endogenous reconstitution of an antiviral
immune response. We have operationally defined two phases in the
kinetics that will be discussed consecutively: phase 1 is characterized
by pulmonary infiltrates and acute infection of the lungs, while phase
2 is characterized by the persistence of interstitial T cells during viral latency after clearance of productive infection.
Phase 1 scenario: CD8 T cells prevent disseminated viral
pneumonia.
The acute phase of pulmonary mCMV infection after
syngeneic BMT was characterized by a vigorous and preferential
recruitment of reconstituted CD8 T cells that confined the infection by
the formation of inflammatory foci. This process was independent of CD4
T cells. The infection of the lungs was moderate, with only ca. 0.04%
(ca. 25,000 cells) of the lung stromal and parenchymal cells expressing
viral IE1 protein at the peak of infection. At the same time, the
number of CD8 T cells in the infiltrates was ca. 5 million, that is,
ca. 200 CD8 T cells were present to control 1 infected cell. The actual
ratio visible in the inflammatory foci was much lower, which is
explained by the fact that infection was already controlled in many
foci. The focal character of the inflammation as well as the
correlation between CD8 T-cell infiltration and decline of the
infection implied an antiviral function of the CD8 T cells. Activation
of the CD8 T cells was indicated by blastoid morphology in the
immunohistology, by a CD62Llo phenotype, and by a
significant proportion of cells that produced IFN-
upon CD3-TCR triggering.
Proof of the protective principle was provided by two complementary
approaches: (i) CD8 T cells isolated from phase 1 infiltrates controlled the infection in cell transfer recipients and (ii) selective
elimination of reconstituting CD8 T cells led to an enhancement of lung
infection by a factor of 100, that is, ca. 4% of the lung cells, or,
in absolute terms, ca. 2.5 million lung cells, were then infected. A
disseminated IP with widening of alveolar septa and partial collapse of
alveoli was seen also after combined depletion of CD4 and CD8 T cells,
that is, in the absence of any T-cell infiltration. It is hence obvious
that phase 1 CMV-IP does not represent a T-cell-driven immunopathology
but is caused primarily by cytolytic infection, with a likely
contribution of cytokines and chemokines secreted by infected cells as
well as by alveolar macrophages and, possibly, by natural killer cells. Clinical observations in BMT recipients have implicated TH2-type cytokines and lack of T-cell-mediated cytotoxicity in the pathogenesis of CMV-IP (47). In a clinical setting, it is difficult to
evaluate the contributions of these two parameters to the pathogenesis. We would propose that the failure in the CD8 T-cell control was decisive for the development of CMV-IP in these patients and that the
TH2-dominated cytokine profile is an epiphenomenon associated with the
CD8 T-cell deficiency. This interpretation is also in accordance with
clinical cases of early CMV-IP occurring prior to engraftment and in
the absence of GvH disease following T-cell depleted allogeneic BMT
(7, 16, 30). In previous models of CMV-IP, reviewed and
interpreted by J. Grundy (13), an apparent lack of
correlation between virus titers and histopathology associated with
T-cell infiltration was used as an argument in favor of the immunopathogenesis hypothesis. Clearly, in our model as well, the lung
histopathology is visually dominated by the infiltrating cells,
particularly at later stages of phase 1 when the number of infected
cells had already declined due to the effect of antiviral CD8 T cells.
It is also evident that antiviral treatment at that stage would not
resolve the histopathological characteristics. Nonetheless, these
infiltrates are protective in that they prevent extensive viral
destruction of the tissue, a conclusion that is in accordance with the
progressive CMV-IP observed in athymic nu/nu mice
(46). The antiviral function of CD8 T cells also explains
the benign course of pulmonary hCMV infection during earlier stages of
AIDS (for a review, see reference 45). While J. Grundy proposed a lack of CD4-driven immunopathology as a result of CD4
T-cell depletion in the patients, we infer from our data obtained by
selective depletion of the CD4 subset (recall Fig. 1 and 2) that
residual CD8 T cells are likely to suffice for controlling the
infection except in later stages of disease, when the numbers of CD8 T
cells have also declined.
In conclusion, timely reconstitution of CD8 T cells is critical for the
termination of acute infection and thus for the prevention of
disseminated viral pneumonia.
Phase 2 scenario: persistence of pulmonary T cells after clearance
of acute infection.
A striking feature is the persistence of
functionally competent pulmonary T cells after clearance of productive
mCMV infection, which is reminiscent of persistent lymphocytosis
observed in survivors of clinical CMV-IP (5). This
CMV-negative IP can be viewed as an "aged" CMV-IP in survivors in
whom the antiviral response has largely prevented viral histopathology.
In fact, the presence of high numbers of interstitial T cells per se
indicated a pathological condition, whereas the alveolar architecture
was apparently intact. With no further information, an association with
CMV is impossible to recognize. The T cells in phase 2 differed from
those in the inflammatory foci of phase 1 by the following features:
(i) they were no longer organized in foci but were randomly distributed in the lung parenchyma, (ii) they were no longer lymphoblasts but were
resting cells by morphological criteria, (iii) the proportion of CD8 T
cells had declined, even though it was still elevated compared with
that in normal lungs or time-matched lungs after BMT with no infection
(19), and (iv) many of the CD8 T cells represented memory
cells, as was indicated by their CD62Lhi phenotype in
conjunction with responsiveness to triggering via their CD3-TCR
complex. The latter property discriminates memory cells from naive
cells, which are also CD62Lhi but are refractory to
triggering by MAb anti-CD3
. Notably, however, a high proportion of
phase 2 CD8 T cells had maintained or possibly reacquired the
CD62Llo phenotype, and a significant proportion of the CD8
T cells were able to respond by producing IFN-
.
A remarkable set of experiments that are related to these findings have
previously been reported by Tanaka et al. (51, 52). After
clearance of acute mCMV infection in the lungs, a fulminant and rapidly
fatal pneumonia was elicited by in vivo application of MAb anti-CD3
.
Since virus recurrence did not occur in the short period until death,
only 24 to 48 h after injection of the MAb, it was obvious that
the pneumonia was not caused by cytolytic virus replication. On the
other hand, the pneumonia was CMV associated in that the effect was not
observed with naive mice. The cause of pneumonia then was a "cytokine
storm," which included IFN-
and tumor necrosis factor alpha
(51), which in turn induced nitric oxide formation via
expression of inducible nitric oxide synthetase (52). In
addition, we propose also direct damage to lung tissue by elicited
cytolytic effector function, such as perforin release, from
memory-effector CD8 T cells. From the facts that virus replication was
clearly not involved in this acute disease and that the pneumonia was
prevented by immunosuppression, the authors believed they had provided
direct evidence for an immunopathogenesis of CMV-IP. In order to
explain the lack of disease in naive mice, they proposed a role for CMV
infection in modulating the responsiveness of pulmonary T cells to
stimulation via the CD3
molecule of the CD3-TCR complex.
We have here documented that the proposed modulation of T-cell
responsiveness does indeed occur as a result of CMV infection. What has
actually happened in the experiments performed by Tanaka and
colleagues? In essence, they have observed the in vivo consequences of
polyclonal T-cell stimulation via the CD3-TCR complex, that is, the in
vivo correlate of the in vitro CD3
-redirected lysis assay and the
CD3
-mediated induction of IFN-
synthesis. A quantitative comparison between phase 2 pulmonary infiltrates of infected and uninfected BMT recipients makes it obvious why pneumonia is induced preferentially in the infected group: the extrapolated number of CD8 T
cells at 3 months after BMT and infection was ca. 0.5 million per lung,
of which 26.4% (recall Fig. 6) were able to respond with IFN-
synthesis, that is, ca. 105 CD8 T cells had the potential
to respond to in vivo polyclonal stimulation. For BMT with no
infection, the extrapolated number of CD8 T cells was ca. 40,000 per
lung, of which only 5.4% were able to respond with IFN-
synthesis,
that is, only ca. 2000 CD8 T cells had the potential to respond to in
vivo polyclonal stimulation. In summary, mCMV infection in our model of
syngeneic BMT has amplified the number of functionally competent CD8 T
cells residing in the lungs by a factor of 50! In addition, cytokine
production by CD4 T cells will also be stimulated. That a simultaneous
polyclonal in vivo triggering of the effector functions of so many T
cells by MAb anti-CD3
will result in an acute cytokine syndrome and associated pneumonia is evident. Was this now the proof of an immunopathogenesis of late CMV-IP?
Stand-by effector cells: guardians of CMV latency?
The
experiments by Tanaka et al. (51, 52) as well as the data
presented here have identified a powerful CMV-amplified response
potential of the pulmonary CD8 T-cell population, and this indeed
entails a risk of immunopathogenesis. However, disease will develop
only if the effector functions are called up by polyclonal stimulation.
At the moment, we see no disease correlate for such polyclonal in vivo
triggering via the CD3-TCR complex, but there may be risk factors that
could elicit immunopathogenesis mediated by the tissue-resident T
cells. After allogeneic BMT, recruitment of antiviral CD8 T cells into
the lungs by CMV-associated chemokines might indeed also attract
GvH-reactive donor T cells, as was implied by the immunopathogenesis
hypothesis (14). However, there is a major problem with this
idea: while the statistical correlation between clinical GvH disease
and human CMV-IP is undoubted, owing to the Minnesota Bone Marrow
Transplantation Program study published in 1986 (27), the
authors of this study have specifically emphasized that GvH disease
preceded symptomatic hCMV infection by more than a month. One may
therefore rather propose that GvH disease causes lung damage, which
predisposes the lungs to fulminant CMV infection resulting in CMV-IP.
What else can be the physiological role of the persisting pulmonary T
cells? An evident hint for answering this question was given by the
antiviral efficacy of phase 2 CD8 T cells in adoptive transfer
recipients. We propose that these cells represent tissue-resident "stand-by" effector cells ready for eliminating latently infected lung cells before virus recurrence, as soon as reactivation of viral
gene expression has led to the presentation of antigenic peptides.
There is clear evidence in support of an immunosurveillance function of
T cells in maintaining CMV latency in general and specifically also in
the lungs. We have shown previously in the murine model that the lungs
carry a particularly high load of latent mCMV genome that entails a
high statistical risk of intermittent transcriptional reactivation
(3, 37, 49). However, infectious virus remained undetectable
(24) unless an immunoablative treatment was performed
(22-24, 49). These experiments have also demonstrated that
recurrent virus can indeed originate from lung tissue and does not have
to be imported from a distant site (23). Notably, as shown
by Polic et al. (34), selective depletion of lymphocyte subsets revealed a redundant and hierarchical control of mCMV latency,
with CD8 T cells being the principal subset.
In a way, the stand-by effector cells are reminiscent of any ordinary
memory T cell, with the notable exception that they stay long term at
the extralymphoid tissue site and that a significant subpopulation
display the CD62Llo phenotype of acutely sensitized
memory-effector cells, as opposed to the CD62Lhi phenotype
of quiescent memory T cells in lymphoid tissues. Taken together, both
features are likely to reflect a frequent engagement of CD8 T cells in
antiviral responses that keeps them busy and causes them to reside long
term in the lungs. Analysis of viral transcription in latently infected
lungs has in fact revealed a focal and random transcription of the
immediate-early gene ie1, with a frequency of ca. 10 transcriptional events per lung at any moment in time (22,
23). If this transcription leads to presentation of antigenic
peptides, specifically of the immunodominant ie1-encoded
nonapeptide YPHFMPTNL (for a review, see reference 36), only a few CD8 T cells out of the large pool of
stand-by memory-effector cells would be needed to terminate primordial reactivation. Such a limited and local delivery of effector functions would not be associated with any notable tissue damage. We propose that
transient but iterative presentation of antigenic peptides based on the
observed random transcriptional activity (22) accounts for
frequent pulses of memory T-cell stimulation. Such a mechanism explains
the persistence of pulmonary infiltrate CD8 T cells in latently
infected lungs.
Conclusion.
The murine model presented here has given
experimental evidence against an immunopathogenesis of primary CMV-IP.
In the acute phase, protective antiviral CD8 T cells confine viral
replication to inflammatory foci and eventually terminate productive
infection of the lungs. Disseminated CMV-IP is caused by extensive
cytolytic infection in the absence of CD8 T cells and with no
pathogenetic involvement of CD4 T cells. After resolution of productive
infection, stand-by memory-effector cells remain in the lungs as
guardians of viral latency. Their elimination by secondary
immunoablative events (23, 34) can result in virus
recurrence and late CMV disease. In addition, the persistence of
tissue-resident memory-effector cells in the lungs entails a risk of
immunopathogenesis after unspecific polyclonal triggering of the T-cell
effector functions under disease conditions that still need to be defined.
 |
ACKNOWLEDGMENTS |
We thank Ronda Cardin (at the time of this study at St. Jude
Children's Research Hospital, Memphis, Tenn.) for her detailed protocol of intracellular IFN-
staining after polyclonal
stimulation. We appreciated the expert technical assistance of Doris
Thomas and Doris Dreis. Claudia Trummer helped by searching literature.
Support was provided by the Deutsche Forschungsgemeinschaft,
Sonderforschungsbereich 490, individual project B1, "Immune control of latent cytomegalovirus infection," and Sonderforschungsbereich 432, individual project A10, "Influence of cytomegalovirus infection on the risk of leukaemia relapse after bone marrow transplantation."
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute for
Virology, Johannes Gutenberg University, Hochhaus am Augustusplatz,
55101 Mainz, Germany. Phone: 49-6131-39-33650. Fax: 49-6131-39-35604. E-mail: Matthias.Reddehase{at}uni-mainz.de.
Present address: Miltenyi Biotec GmbH, 51429 Bergisch-Gladbach, Germany.
 |
REFERENCES |
| 1.
|
Alterio de Goss, M.,
R. Holtappels,
H.-P. Steffens,
J. Podlech,
P. Angele,
L. Dreher,
D. Thomas, and M. J. Reddehase.
1998.
Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.
J. Virol.
72:7733-7744[Abstract/Free Full Text].
|
| 2.
|
Ashton-Rickardt, P. G., and J. T. Opferman.
1999.
Memory T lymphocytes.
Cell. Mol. Life Sci.
56:69-77[CrossRef][Medline].
|
| 3.
|
Balthesen, M.,
M. Messerle, and M. J. Reddehase.
1993.
Lungs are a major organ site of cytomegalovirus latency and recurrence.
J. Virol.
67:5360-5366[Abstract/Free Full Text].
|
| 4.
| Barry, S. M., M. A. Johnson, and G. Janossy. Cytopathology or immunopathology? The puzzle of
cytomegalovirus pneumonitis revisited. Bone Marrow Transplant., in
press.
|
| 5.
|
Chien, S. M.,
C. K. Chan,
G. Kasupski,
D. Chamberlain,
G. Fyles, and H. Messner.
1992.
Long-term sequelae after recovery from cytomegalovirus pneumonia in allogeneic bone marrow transplant recipients.
Chest
101:1000-1004[Abstract/Free Full Text].
|
| 6.
|
Cobbold, S. P.,
A. Jayasuriya,
A. Nash,
T. D. Prospero, and H. Waldmann.
1984.
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.
Nature (London)
312:548-550[CrossRef][Medline].
|
| 7.
|
Couriel, D.,
J. Canosa,
H. Engler,
A. Collins,
C. Dunbar, and A. J. Barrett.
1996.
Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies.
Bone Marrow Transplant.
18:347-353[Medline].
|
| 8.
|
DeGrendele, H. C.,
P. Estess, and M. H. Siegelman.
1997.
Requirement for CD44 in activated T cell extravasation into an inflammatory site.
Science
278:672-675[Abstract/Free Full Text].
|
| 9.
|
Dobonici, M.,
J. Podlech,
H.-P. Steffens,
S. Maiberger, and M. J. Reddehase.
1998.
Evidence against a key role for transforming growth factor- 1 in cytomegalovirus-induced bone marrow aplasia.
J. Gen. Virol.
79:867-876[Abstract].
|
| 10.
|
Einsele, H.,
H. Hebart,
C. Bokemeyer,
L. Kanz,
G. Jahn, and C. A. Müller.
1998.
Cytomegalovirus infection following hematopoietic stem cell transplantation.
Monogr. Virol.
21:106-118.
|
| 11.
|
Enright, H.,
R. Haake,
D. Weisdorf,
N. Ramsay,
P. McGlave,
J. Kersey,
W. Thomas,
D. McKenzie, and W. Miller.
1993.
Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy.
Transplantation
55:1339-1346[Medline].
|
| 12.
|
Gallatin, W. M.,
I. L. Weissman, and E. C. Butcher.
1983.
A cell surface molecule involved in organ-specific homing of lymphocytes.
Nature
304:30-34[CrossRef][Medline].
|
| 13.
|
Grundy, J. E.
1990.
Virologic and pathogenetic aspects of cytomegalovirus infection.
Rev. Infect. Dis.
12(Suppl. 7):S711-S719.
|
| 14.
|
Grundy, J. E.,
J. D. Shanley, and P. D. Griffiths.
1987.
Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?
Lancet
ii:996-999.
|
| 15.
|
Grundy, J. E.,
J. D. Shanley, and G. M. Shearer.
1985.
Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis.
Transplantation
39:548-553[Medline].
|
| 16.
|
Hertenstein, B.,
W. Hampl,
D. Bunjes,
M. Wiesneth,
C. Duncker,
U. H. Koszinowski,
H. Heimpel,
R. Arnold, and T. Mertens.
1995.
In vivo/ex vivo T cell depletion for GvHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.
Bone Marrow Transplant.
15:387-393[Medline].
|
| 17.
|
Ho, M.
1990.
Epidemiology of cytomegalovirus infection.
Rev. Infect. Dis.
12:701-710.
|
| 18.
|
Ho, M.
1995.
Cytomegaloviruses, p. 1351-1364.
In
G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
|
| 19.
|
Holtappels, R.,
J. Podlech,
G. Geginat,
H.-P. Steffens,
D. Thomas, and M. J. Reddehase.
1998.
Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.
J. Virol.
72:7201-7212[Abstract/Free Full Text].
|
| 20.
|
Holtappels, R.,
D. Thomas,
J. Podlech,
G. Geginat,
H.-P. Steffens, and M. J. Reddehase.
2000.
The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells.
J. Virol.
74:1871-1884[Abstract/Free Full Text].
|
| 21.
|
Koszinowski, U. H.,
M. J. Reddehase, and S. Jonjic.
1993.
The role of T-lymphocyte subsets in the control of cytomegalovirus infection, p. 429-445.
In
D. B. Thomas (ed.), Viruses and the cellular immune response. Marcel Dekker, Inc., New York, N.Y.
|
| 22.
|
Kurz, S. K.,
M. Rapp,
H.-P. Steffens,
N. K. A. Grzimek,
S. Schmalz, and M. J. Reddehase.
1999.
Focal transcriptional activity of murine cytomegalovirus during latency in the lungs.
J. Virol.
73:482-494[Abstract/Free Full Text].
|
| 23.
|
Kurz, S. K., and M. J. Reddehase.
1999.
Patchwork pattern of transcriptional reactivation in the lungs indicates sequential checkpoints in the transition from murine cytomegalovirus latency to recurrence.
J. Virol.
73:8612-8622[Abstract/Free Full Text].
|
| 24.
|
Kurz, S. K.,
H.-P. Steffens,
A. Mayer,
J. R. Harris, and M. J. Reddehase.
1997.
Latency v |